Medical Laboratory Observer: Liquid biopsy and droplet digital PCR offer improvements for lung cancer testing

Posted on

[et_pb_section bb_built=”1″][et_pb_row][et_pb_column type=”4_4″][et_pb_text _builder_version=”3.0.82″ background_layout=”light” border_style=”solid” box_shadow_position=”outer”]

“…the growing use of ddPCR assays for identifying the subset of patients who should be placed on targeted therapy options is providing carefully measured results with rapid turnaround time for optimal clinical utility. This approach enabled by liquid biopsy means that physicians do not have to wait weeks for genomic information that may enable the use of a targeted therapeutic against a patient’s cancer, unlike slower molecular analytic methods that often necessitate starting patients on a general chemotherapy regimen until results are received.”


Read the full story.